Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dermira Inc (DERM)

Dermira Inc (DERM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 448,708
  • Shares Outstanding, K 54,521
  • Annual Sales, $ 42,340 K
  • Annual Income, $ -221,540 K
  • 60-Month Beta 1.33
  • Price/Sales 8.98
  • Price/Cash Flow N/A
  • Price/Book 26.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.41
  • Number of Estimates 3
  • High Estimate -1.23
  • Low Estimate -1.64
  • Prior Year -1.70
  • Growth Rate Est. (year over year) +17.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.25 +53.33%
on 10/16/19
9.27 -13.16%
on 11/08/19
+2.36 (+41.48%)
since 10/11/19
3-Month
5.25 +53.33%
on 10/16/19
9.48 -15.08%
on 09/11/19
-0.35 (-4.17%)
since 08/09/19
52-Week
5.25 +53.33%
on 10/16/19
15.48 -48.00%
on 04/08/19
-2.51 (-23.77%)
since 11/09/18

Most Recent Stories

More News
Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with...

DERM : 8.05 (-2.19%)
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with...

DERM : 8.05 (-2.19%)
The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

MRK : 83.28 (-0.37%)
RTRX : 12.77 (-0.62%)
DERM : 8.05 (-2.19%)
LHCG : 127.24 (+0.70%)
Pharma Sector Tops in October: Best ETFs & Stocks

Pharma sector wins in October, making these ETFs and stocks winners.

PPH : 59.45 (-0.52%)
XPH : 38.57 (-0.59%)
PJP : 60.08 (-0.28%)
ALXN : 109.01 (-1.61%)
BIIB : 294.14 (+0.30%)
ACHN : 6.35 (-0.16%)
DERM : 8.05 (-2.19%)
GLYC : 5.90 (-5.45%)
RIGL : 2.31 (+2.67%)
IRWD : 11.11 (+0.82%)
Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks

The healthcare sector seems to be least affected by a protracted U.S.-China trade war. Stellar third-quarter earnings make the sector a hotbed for money.

MRK : 83.28 (-0.37%)
RTRX : 12.77 (-0.62%)
DERM : 8.05 (-2.19%)
LHCG : 127.24 (+0.70%)
Dermira has the Best Relative Performance in the Pharmaceuticals Industry (DERM , LLY , LCI , BMY , ZTS )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

DERM : 8.05 (-2.19%)
LLY : 112.80 (-0.64%)
LCI : 8.76 (-1.90%)
Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales

Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.

IRWD : 11.11 (+0.82%)
DERM : 8.05 (-2.19%)
JAZZ : 130.88 (+0.57%)
FGEN : 35.40 (-14.94%)
Dermira (DERM) Reports Q3 Loss, Tops Revenue Estimates

Dermira (DERM) delivered earnings and revenue surprises of 24.29% and 4.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

DERM : 8.05 (-2.19%)
Dermira: 3Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Dermira Inc. (DERM) on Tuesday reported a loss of $57.6 million in its third quarter.

DERM : 8.05 (-2.19%)
Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update

--- Phase 3 lebrikizumab program initiated in adult and adolescent patients with moderate-to-severe atopic dermatitis

DERM : 8.05 (-2.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade DERM with:

Business Summary

Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage...

See More

Key Turning Points

2nd Resistance Point 8.46
1st Resistance Point 8.26
Last Price 8.05
1st Support Level 7.89
2nd Support Level 7.72

See More

52-Week High 15.48
Fibonacci 61.8% 11.57
Fibonacci 50% 10.36
Fibonacci 38.2% 9.16
Last Price 8.05
52-Week Low 5.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar